NEW YORK, Sept. 4-Novartis and Compugen are extending their research collaboration to include target validation and RNA interference research, the two companies said today.
The two companies intend to build a large-scale platform that can generate a library of transcript-inhibiting molecules. Compugen will own the platform and have rights to use it internally and as a commercial product. Novartis will use the system for its own research and will own the results of that work.
Novartis plans to use the RNAi platform to synthesize transcript-inhibiting molecules and use them to validate targets and evaluate gene function.
Last August, Compugen struck a major platform licensing and DNA chip design deal with Novartis as part of the pharmaceutical giant's efforts to establish a comprehensive human transcriptome database.
For further information, see the press release.